Physician profile
Michelle Head
NPI 1568929826
$6,224.52
in general payments reported to CMS, 2019-2025
18 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $974 · 2023: $2,087 · 2024: $1,865 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,624.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $749.14 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $716.26 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $707.99 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neuronetics, INC. | $582.98 | 2024 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $413.13 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $406.82 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $336.68 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $314.94 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $276.26 | 2021-2025 | Trintellix |
| Lundbeck LLC | $211.99 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $143.67 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $141.85 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $130.81 | 2022-2025 | Azstarys |
| Tris Pharma INC | $20.04 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $19.77 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.98 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $16.33 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.